Document is current

Article History

Received: 23 March 2023

Accepted: 23 May 2024

First Online: 31 May 2024

Declarations

:

: All methods were carried out in accordance with relevant guidelines and regulations. This study was conducted as secondary research using deidentified data licensed from a third party, Vestrum Health. The data had identifying patient information removed and were coded in such a way that the data could not be linked back to subjects from whom they were originally collected prior to the authors gaining access to it. The study was reviewed and considered exempt from institutional review board (IRB) approval by the WCG IRB (Seattle, Washington, USA), under 45 CFR § 46.104(d)(4). As the study did not involve human subjects or research based on identifiable patient data, the study does not fall under the remit of the Declaration of Helsinki.

: Not applicable.

: Andrew A. Moshfeghi reports serving as a consultant to Allergan, Alimera Sciences, Ainsly Ltd/Waldo Inc., Annexon Therapeutics, Inc., Apellis, Inc., Genentech/Roche, Graybug, Novartis, Ocular Therapeutix, OcuTerra Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Pr3vent, RegenxBio, SciNeuro, Inc., and Valitor, Inc.; contracted research with Genentech/Roche, Novartis, and Regeneron Pharmaceuticals, Inc.; and ownership interest in Ainsly Ltd/Waldo Inc., Ocular Therapeutix, Placid0, and Pr3vent.Rahul N. Khurana is a consultant to Arrowhead Pharmaceuticals, Bausch + Lomb, Genentech, NGM Biopharmaceuticals, Ophthea and Regeneron Pharmaceuticals, Inc.; and has received research funding from Annexion, Apellis, Chengdu Kanghong, Clearside Biomedical, EyePoint, Genentech, NGM Biopharmaceuticals, Opthea, Oxurion, and RegenxBio.Hadi Moini, Steven Sherman, and Kimberley Reed are employees of and hold shares in Regeneron Pharmaceuticals, Inc.Nick Boucher is a salaried employee of Vestrum Health.Ehsan Rahimy is a consultant to Regeneron Pharmaceuticals, Inc.